Physician profile
Robert S Garcia
NPI 1184622136
$23,513.65
in general payments reported to CMS, 2019-2025
40 companies · $4,996 in 2025
The $4,996 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,115 · 2020: $2,113 · 2021: $3,013 · 2022: $3,222 · 2023: $3,735 · 2024: $4,319 · 2025: $4,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,788.01 |
| Education | $262.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,236.79 | 2020-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $1,840.44 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $1,809.71 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,755.18 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,683.63 | 2021-2025 | |
| Lundbeck LLC | $1,425.06 | 2019-2025 | Rexulti, Brintellix |
| Tris Pharma INC | $1,346.08 | 2019-2025 | Dyanavel Xr |
| Alkermes, INC. | $1,187.08 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Supernus Pharmaceuticals, INC. | $1,083.27 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $1,014.09 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $962.06 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $892.64 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $774.58 | 2022-2025 | Ingrezza |
| Validus Pharmaceuticals LLC | $729.64 | 2022-2025 | Equetro, Raldesy, Equetro |
| Ironshore Pharmaceuticals INC. | $644.49 | 2019-2024 | Jornay Pm |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $601.14 | 2019-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $403.94 | 2022-2025 | Quviviq, Quviviq |
| Teva Pharmaceuticals USA, INC. | $394.06 | 2024-2025 | Uzedy, Austedo Xr |
| Neos Therapeutics, Lp | $374.70 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Almatica Pharma LLC | $313.94 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $243.62 | 2020-2025 | Fanapt |
| Noven Therapeutics, LLC | $212.52 | 2023-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $185.82 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.00 | 2019 | |
| Allergan, INC. | $173.64 | 2020 | |
| Eisai INC. | $164.44 | 2020 | |
| Collegium Pharmaceutical, INC. | $151.93 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $142.62 | 2025 | Cobenfy |
| Shire North American Group INC | $124.24 | 2019 | |
| Biogen, INC. | $84.85 | 2021-2022 | |
| Harmony Biosciences LLC | $68.06 | 2020-2021 | |
| Indivior INC. | $53.84 | 2019 | |
| Alfasigma USA, INC. | $52.19 | 2020-2021 | |
| Novo Nordisk INC | $47.30 | 2024 | |
| Owp Pharmaceuticals, INC. | $43.87 | 2022-2024 | Subvenite |
| Avadel Cns Pharmaceuticals, LLC | $33.94 | 2025 | Lumryz |
| Sage Therapeutics, LLC | $26.60 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $21.52 | 2023 | Methylphenidate Hydrochloride |
| Livanova USA, INC. | $17.84 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.